- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01954329
Markers in the Diagnosis of TIA (MIND-TIA)
MIND-TIA is primarily an observational diagnostic study that aims to evaluate the role of novel biomarkers in the diagnosis of Transient Ischemic Attack (TIA)in primary care.
Rapid and adequate diagnosis of TIA is of great importance to enable a rapid start of treatment, and thereby decrease the risk of subsequent ischemic stroke.
Study Overview
Status
Conditions
Detailed Description
Rationale:
A Transient Ischaemic Attack (TIA) does not cause permanent damage of brain tissue, but the risk of a subsequent ischemic stroke in the short term is high. Timely recognition of TIA would result in early treatment and reduce the risk of ischaemic stroke, and other adverse cardiovascular events.
To improve the management of TIA adequate diagnosis is of imminent importance. However the diagnosis is notoriously difficult, for both GP and neurologist.
Adequate biomarkers for brain ischaemia could improve the early diagnosis and thus the subsequent management of TIA.
Objectives:
To assess the added diagnostic value of biomarkers beyond the clinical assessment (medical history, signs and symptoms) in patients suspected of TIA.
Secondary objectives
- To assess the prognostic value of biomarkers in patients with an established diagnosis of TIA.
- To assess the time delay and factors related to delay in patients suspected of TIA.
Study population:
350 adult persons suspected of TIA from primary care.
Methods:
Recruitment of patients will be performed at the general practices of 200 GPs in the vicinity of 4 to 5 participating hospitals. During a home visit a research nurse collects a blood sample, and takes two health-related questionnaires. Participants will be referred by their GP to the regional TIA outpatient clinic for additional investigations, including brain imaging. The diagnostic accuracy of a set of biomarkers will be assessed with the 'definite' diagnosis of TIA by a panel of neurologists as the reference standard.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3508 GA
- Recruiting
- Julius Center UMC Utrecht
-
Sub-Investigator:
- Faas LS Dolmans, MD
-
Principal Investigator:
- Frans H Rutten, MD, PhD
-
Sub-Investigator:
- Marie-Louise EL Bartelink, MD, PhD
-
Sub-Investigator:
- Jaap LJ Kappelle, MD, PhD
-
Sub-Investigator:
- Arno W Hoes, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being adult (18 years and older)
- Presenting to the GP with a new episode of symptoms suspected of TIA and the GP considering further investigations to confirm or exclude TIA at the TIA outpatient clinic.
- A blood sample can be collected within 72 hours after onset of symptoms.
Exclusion Criteria:
- The patient still has active symptoms or signs suspected of an ongoing ischemic stroke and immediate referral to the neurologist seems indicated.
- Valid history taking is impossible because of severe cognitive impairment or insufficient knowledge of the Dutch language.
- Patient with a life expectancy of < 6 months.
- Patient is not willing or able to give written informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients suspected of TIA by the GP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
'Definite' Diagnosis of TIA
Time Frame: After 6 months of follow-up
|
Determined by expert panel consisting of 3 neurologists
|
After 6 months of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ischemic stroke and other cardiovascular events
Time Frame: During 6 months of follow-up
|
Assessed in the medical records of the GPs
|
During 6 months of follow-up
|
Time delay to GP consultation and start of treatment
Time Frame: 1 day of home visit
|
1 day of home visit
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Dolmans LS, Rutten F, Bartelink MEL, van Dijk EJ, Nederkoorn PJ, Kappelle J, Hoes AW; MIND-TIA study group. Serum biomarkers in patients suspected of transient ischaemic attack in primary care: a diagnostic accuracy study. BMJ Open. 2019 Oct 17;9(10):e031774. doi: 10.1136/bmjopen-2019-031774.
- Dolmans LS, Rutten FH, El Bartelink ML, Seppenwoolde G, van Delft S, Kappelle LJ, Hoes AW. Serum biomarkers for the early diagnosis of TIA: The MIND-TIA study protocol. BMC Neurol. 2015 Jul 28;15:119. doi: 10.1186/s12883-015-0388-z.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL43627.041.13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transient Ischemic Attack
-
Lawson Health Research InstituteHeart and Stroke Foundation of OntarioCompleted
-
University of California, San DiegoWithdrawnStroke | Transient Ischemic Attack (TIA)United States
-
Hamad Medical CorporationUnknownStroke | Transient Ischemic Attack (TIA)Qatar
-
Versailles HospitalCompletedCryptogenic Transient Ischemic Attack and Minor StrokeFrance
-
University of NottinghamNottingham University Hospitals NHS Trust; The Stroke Association, United KingdomCompletedStroke | Transient Ischaemic AttackUnited Kingdom
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Uppsala County Council, SwedenUnknownAcute Stroke | TIA (Transient Ischemic Attack)Sweden
-
AstraZenecaCompletedAcute Ischaemic Stroke | Transient Ischaemic AttackBelgium, France, Italy, Spain, Sweden, Thailand, Germany, Korea, Republic of, Brazil, Hungary, India, Mexico, Vietnam, China, Taiwan, Hong Kong, Slovakia, Australia, Poland, Saudi Arabia, Ukraine, Canada, Russian Federation, Bulgaria, R... and more
-
University of AlbertaHeart and Stroke Foundation of Canada; Alberta Heritage Foundation for Medical...CompletedIschemic Stroke | Transient Ischemic AttacksCanada
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownStroke | Transient Ischaemic Attack